Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CRX 100

Next Previous
Drug Profile

CRX 100

Alternative Names: CRX-100

Latest Information Update: 26 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer BioEclipse Therapeutics
  • Class Antineoplastics; Cell therapies; Oncolytic viruses
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Ovarian cancer

Most Recent Events

  • 24 Jun 2019 Preclinical trials in Cancer (In children) in USA (IV) before June 2019
  • 24 Jun 2019 BioEclipse Therapeutics plans to file an IND application with US FDA for Solid tumours (Second-line therapy or greater) by the end of 2019
  • 24 Jun 2019 BioEclipse Therapeutics plans a phase Ib/IIa trial for Solid tumours (Second-line therapy or greater) in USA during the first quarter of 2020 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top